Archives
-
In Vitro Drug Response Metrics in Cancer
2026-09-21
Hannah R. Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of anticancer drug response. This framework helps researchers design time-resolved assays, interpret cytotoxicity more precisely, and avoid treating reduced viability as direct evidence of cell killing.
-
Amyloid Beta-peptide (25-35) Workflow Guide
2026-09-21
Build a controlled Aβ25-35 neurotoxicity workflow that connects neuronal injury, oxidative stress, and microglial polarization readouts. This guide combines practical handling, assay design, troubleshooting, and the FLOT1–FOSL2–EphA2 findings to strengthen Alzheimer’s disease neurotoxicity models.
-
Rucaparib in DNA Repair and Radiosensitization
2026-09-20
Rucaparib (AG-014699) provides a practical PARP1 inhibition workflow for connecting DNA damage, repair deficiency, and treatment response. This guide translates radiosensitization and spliceosome-linked PARP sensitivity into controllable in vitro assays, with emphasis on dosing, timing, imaging, and troubleshooting.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-09-19
The reference preprint proposes that RNA polymerase II degradation can activate cell death through mechanisms that are not explained by global transcriptional loss alone. Its separation-of-function framework is relevant to cancer biology research because it distinguishes the consequences of removing a core transcriptional protein from those caused by broadly suppressing RNA synthesis.
-
Diethylmaleate for GSH Depletion Workflows
2026-09-19
Diethylmaleate provides a practical chemical route to lower intracellular glutathione and reveal redox-dependent biology. This guide connects reproducible GSH-depletion workflows with GST-mediated insecticide resistance, cell stress assays, toxicology, and reproductive redox research.
-
MK-4827 (Niraparib) for PARP Research
2026-09-18
Build reproducible PARP inhibition experiments with MK-4827 (Niraparib), from BRCA-mutant viability assays to radiosensitization and spliceosome-linked hepatocellular carcinoma models. The workflow emphasizes dosing discipline, orthogonal DNA-damage readouts, and careful translation of reference findings into testable combination studies.
-
URB597 Workflows for FAAH and Pain Research
2026-09-17
URB597 (KDS-4103) provides a selective way to elevate anandamide and interrogate FAAH-dependent endocannabinoid signaling in neuronal, inflammatory, and pain models. This practical guide connects assay setup, temporal sampling, behavioral phenotyping, and troubleshooting to the latest cannabidiol pain research.
-
AP-2α, MGMT, and TMZ Resistance in Recurrent GBM
2026-09-17
The reference study identifies AP-2α as a transcriptional suppressor of MGMT in recurrent glioblastoma and links this pathway to restored temozolomide responsiveness. Its combination of promoter-binding assays, DNA-damage measurements, resistant glioma models, and intracranial studies provides a mechanistic framework for understanding and potentially reversing TMZ resistance.
-
AZD2461 Workflow for DNA Repair Research
2026-09-17
Build more informative breast cancer assays with AZD2461, a novel PARP inhibitor that combines PARP-1 pathway interrogation with resistance-focused experimental design. A paired analysis of viability, cell death, cell-cycle state, and PAR engagement helps distinguish cytostatic responses from true cytotoxicity.
-
Rucaparib (AG-014699) Experimental Workflows
2026-09-16
Rucaparib (AG-014699) enables controlled studies of PARP1 inhibition, persistent DNA breaks, and radiosensitization in repair-deficient cancer models. This guide connects practical dose-response and imaging workflows with the 2025 discovery that RNA Pol II loss can activate regulated apoptosis independently of transcriptional shutdown.
-
Diethylmaleate: From Redox Tool to Translation
2026-09-15
Diethylmaleate is more than a glutathione-depleting reagent: it is a practical perturbation tool for testing whether redox buffering drives toxicity, resistance, apoptosis, or tissue injury. This article connects mechanistic evidence with translational study design, emphasizing controls, cross-domain limits, and decision-ready experimental workflows.
-
Melittin in GPCR and Glioblastoma Research
2026-09-15
Melittin provides a rapid chemical perturbation of Gs- and Gi-linked signaling for studies that connect GPCR activity with migration, apoptosis, and ferroptosis. This workflow-focused guide shows how to use the bioactive peptide alongside the miR-18a/ALOXE3 glioblastoma model while controlling for nonspecific cytotoxicity and preparation-related variability.
-
7-dehydro Cholesterol: Applied Research Workflows
2026-09-14
Turn 7-dehydro Cholesterol into a controlled probe of DHCR7 flux, UVB-initiated vitamin D3 formation, and oxidation-sensitive sterol biology. This practical guide connects cell and skin-model assays to the dhcr7-edited grass carp study while separating substrate supplementation from a true gene-loss phenotype.
-
SmD2 Acetylation and PARP Sensitivity in HCC
2026-09-14
A 2024 Nature Communications study identifies acetylation-dependent control of the spliceosome protein SmD2 as a regulatory link between alternative splicing, BRCA1/FANC expression, DNA repair, and PARP inhibitor sensitivity in hepatocellular carcinoma. The findings support biomarker-led investigation of SmD2 and the p300–HDAC2 axis, including combination strategies with HDAC and PARP inhibition in BRCA-proficient HCC models.
-
Olsalazine Sodium: Reliable Assay Workflows
2026-09-13
Learn how Olsalazine Sodium (SKU A8490) can support reproducible inflammation, colorectal cancer, viability, and proliferation workflows. This scenario-based guide addresses solvent compatibility, preparation, controls, interpretation, and practical product-selection criteria using documented quantitative data and a 2025 transporter study.